Corporate
About ACI
Team
Our Approach
Alzheimer’s Disease
ALPHA-1062
Traumatic Brain Injury
Amyotrophic Lateral Sclerosis
ALPHA-0602
Our Pipeline
Investors
Stock Info
News
Presentations
Investor Relations Contact
Contact
Menu
Corporate
About ACI
Team
Our Approach
Alzheimer’s Disease
ALPHA-1062
Traumatic Brain Injury
Amyotrophic Lateral Sclerosis
ALPHA-0602
Our Pipeline
Investors
Stock Info
News
Presentations
Investor Relations Contact
Contact
Investors
News
News
Select Year
2021
2020
03.23.2021
Alpha Cognition Presenting at the Benzinga Biotech Small Cap Conference
03.22.2021
Alpha Cognition Announces Closing of Qualifying Transaction
03.08.2021
Crystal Bridge Provides Transaction Update
12.04.2020
Crystal Bridge Announces Receipt by Alpha Cognition of Japanese Patent for Alzheimer Drug Alpha-1062 and Announces Private Placement Updates
10.28.2020
Crystal Bridge Enters into Arrangement Agreement with Alpha Cognition, Announces up to $13 Million Private Placement
07.14.2020
Crystal Bridge Enterprises Announces Letter of Intent for Qualifying Transaction with Alpha Cognition Inc.
06.08.2020
Alpha Cognition, Inc. Attends the BIO Digital Partnering Event This Week
05.12.2020
Alpha Cognition Inc. Announces Granted EU Patents and Orphan Drug Designation for its Progranulin Platform
04.30.2020
Alpha Cognition Inc. Receives FDA/PMDA Regulatory Guidance for Alpha-1062 Alzheimer’s Therapy
04.21.2020
Linical and Alpha Cognition Announce Strategic Partnership to Position Alpha- 1062 for Approval in the Unites States and Japan Alzheimer’s Markets
04.09.2020
Alpha Cognition Inc. Name Change
Investors
Quick Links
Stock Info
News
Presentations
Investor Relations Contact
View Video
Read More
Latest News
View All
View All
TSX-V: ACI
15 min delay
Last
$21.67
Change
$-0.41
Open
21.46
Vol
909746
High
21.94
Low
21.16
Stock Information